Evidence map›Paper›PMID 27457881›Full record

ArticleScientific reports2016

Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation.

Zijiang Yang, John Concannon, Kelvin S Ng, Kathleen Seyb, Luke J Mortensen, Sudhir Ranganath, Fangqi Gu, Oren Levy, Zhixiang Tong, Keir Martyn and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Zijiang YangHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
John ConcannonLaboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US.
Kelvin S NgHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Kathleen SeybLaboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US.
Luke J MortensenRegenerative Bioscience Center, Department of Animal and Dairy Science, and College of Engineering, University of Georgia, Athens, GA, US.
Sudhir RanganathHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Fangqi GuHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Oren LevyHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Zhixiang TongHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Keir MartynHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Weian ZhaoDepartment of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center and Chao Family Comprehensive Cancer Center, Department of Biomedical Engineering, and Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California, Irvine, CA, US.
Charles P LinDepartment of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US.
Marcie A GlicksmanDepartment of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US.
Jeffrey M KarpHarvard-MIT Health Sciences and Technology, Cambridge, MA, US.
Harvard–MIT Division of Health Sciences and Technology · USBrigham and Women's Hospital · USHarvard University · USHarvard NeuroDiscovery Center · USShanghai Industrial Technology Institute · CNUniversity of California, Irvine · USUniversity of Georgia · US

Funding

Engineered Induction of a Stem Cell Homing ResponseR01HL095722 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2018
$3.9M
NHLBI NIH HHS R01 HL095722
6 · The paper itself

Abstract

Pre-treatment or priming of mesenchymal stem cells (MSC) prior to transplantation can significantly augment the immunosuppressive effect of MSC-based therapies. In this study, we screened a library of 1402 FDA-approved bioactive compounds to prime MSC. We identified tetrandrine as a potential hit that activates the secretion of prostaglandin E2 (PGE2), a potent immunosuppressive agent, by MSC. Tetrandrine increased MSC PGE2 secretion through the NF-κB/COX-2 signaling pathway. When co-cultured with mouse macrophages (RAW264.7), tetrandrine-primed MSC attenuated the level of TNF-α secreted by RAW264.7. Furthermore, systemic transplantation of primed MSC into a mouse ear skin inflammation model significantly reduced the level of TNF-α in the inflamed ear, compared to unprimed cells. Screening of small molecules to pre-condition cells prior to transplantation represents a promising strategy to boost the therapeutic potential of cell therapy.

Indexed as

AnimalsBenzylisoquinolinesCyclooxygenase 2HumansImmunomodulationImmunosuppressive AgentsMass ScreeningMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceNF-kappa BRAW 264.7 CellsSignal TransductionSmall Molecule LibrariesBenzylisoquinolinesCyclooxygenase 2Immunosuppressive AgentsNF-kappa BPtgs2 protein, mouseSmall Molecule Librariestetrandrine

Identifiers

PMID27457881
PMCPMC4960598
OpenAlexW2493958312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.